XML 47 R32.htm IDEA: XBRL DOCUMENT
v3.22.4

Revenue (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2022
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue [Table Text Block] | The following table represents our revenues disaggregated by product line (in thousands) and our disaggregated product line revenue as a percentage of total revenue:
| Year ended December 31,
| 2022 |  | 2021 |  | 2020
Product line | Revenue |  | % of Revenue |  | Revenue |  | % of Revenue |  | Revenue |  | % of Revenue
Infusion Consumables | $ | 566,617 |  |  | 25 | % |  | $ | 555,189 |  |  | 42 | % |  | $ | 473,740 |  |  | 37 | %
Infusion Systems | 351,080 |  |  | 15 | % |  | 352,321 |  |  | 27 | % |  | 359,691 |  |  | 28 | %
IV Solutions | 363,472 |  |  | 16 | % |  | 359,477 |  |  | 27 | % |  | 388,971 |  |  | 31 | %
Critical Care | 47,330 |  |  | 2 | % |  | 49,321 |  |  | 4 | % |  | 48,602 |  |  | 4 | %
Infusion Systems-Smiths Medical | 340,124 |  |  | 15 | % |  | — |  |  | nm |  | — |  |  | nm
Vascular Access-Smiths Medical | 326,765 |  |  | 14 | % |  | — |  |  | nm |  | — |  |  | nm
Vital Care-Smiths Medical | 284,609 |  |  | 13 | % |  | — |  |  | nm |  | — |  |  | nm
Total Revenues | $ | 2,279,997 |  |  | 100 | % |  | $ | 1,316,308 |  |  | 100 | % |  | $ | 1,271,004 |  |  | 100 | %
We report revenue on a "where sold" basis, which reflects the revenue within the country or region in which the ultimate sale is made to our external customer. The following table represents our revenues disaggregated by geography (in thousands):
| Year ended December 31,
Geography | 2022 |  | 2021 |  | 2020
United States | $ | 1,460,069 |  |  | $ | 941,809 |  |  | $ | 910,627 |
Europe, the Middle East and Africa | 367,411 |  |  | 147,488 |  |  | 132,763 |
APAC | 257,208 |  |  | 85,692 |  |  | 79,610 |
Other Foreign | 195,309 |  |  | 141,319 |  |  | 148,004 |
Total Revenues | $ | 2,279,997 |  |  | $ | 1,316,308 |  |  | $ | 1,271,004 |
Domestic sales accounted for 64%, 72% and 72% of total revenue in 2022, 2021 and 2020, respectively. International sales accounted for 36%, 28% and 28% of total revenue in 2022, 2021 and 2020, respectively.
Contract with Customer, Asset and Liability [Table Text Block] | Our contract balances (deferred revenue) are recorded in accrued liabilities and other long-term liabilities in our consolidated balance sheet (see Note 10: Accrued Liabilities and Other Long-term Liabilities). The following table presents the changes in our contract balances for the years ended December 31, 2022 and 2021, (in thousands):
| Contract Liabilities
Beginning balance, January 1, 2021 | $ | (6,430) |
Equipment revenue recognized | 10,048 |
Equipment revenue deferred due to implementation | (13,725) |
Software revenue recognized | 7,261 |
Software revenue deferred due to implementation | (4,615) |
Ending balance, December 31, 2021 | (7,461) |
Fair value of acquired deferred revenue | (51,245) |
Equipment revenue recognized | 32,252 |
Equipment revenue deferred due to implementation | (20,332) |
Software revenue recognized | 16,277 |
Software revenue deferred due to implementation | (17,557) |
Government grant deferred revenue | (3,729) |
Government grant recognized | 1,514 |
Other deferred revenue | (1,500) |
Other deferred revenue recognized | 5,915 |
Ending balance, December 31, 2022 | $ | (45,866) |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction | As of December 31, 2022, revenue from remaining performance obligations is as follows:
| Recognition Timing
(in thousands) | <12 Months |  | > 12 Months
Equipment revenue | $ | (15,144) |  |  | $ | (982) |
Software revenue | (8,277) |  |  | (1,026) |
Government grant revenue | (1,422) |  |  | (12,797) |
Other deferred revenue* | (4,784) |  |  | (1,434) |
Total | $ | (29,627) |  |  | $ | (16,239) |

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of expected timing for satisfying remaining performance obligation. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b)(1) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration